| Bioactivity | Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders. |
| Target | Dopamine, mACh receptor |
| Invitro | Substituted benzamides have been shown to possess a number of pharmacological properties most of which are related to their ability to antagonize the central and peripheral effects of dopamine and/or facilitate the release of acetylcholine on to muscarinic receptors in the gastrointestinal smooth muscle. This has led to their successful clinical use as antiemetic and in the treatment of a wide range of gastrointestinal disorders of somatic, psychosomatic and iatrogenic origin[1]. |
| Name | Benzamide Derivative 1 |
| CAS | 108226-05-7 |
| Formula | C22H34ClN3O3 |
| Molar Mass | 423.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Noverola V, et al. Preparation and formulation of N-heterocyclyl-substituted benzamides useful in treatment of gastrointestinal disorders. EP0213775A1. |
Benzamide Derivative 1
CAS: 108226-05-7 F: C22H34ClN3O3 W: 423.98
Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be use
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.